Atrix patent extends patent protection on prostate cancer product.Atrix Laboratories, Inc. (Fort Collins, CO) announced that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property issued United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent 6,565,874, which effectively extends patent protection for the prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. products franchise, Eligard (leuprolide acetate leu·pro·lide acetate n. A synthetic polypeptide analog of naturally occurring gonadotropin-releasing hormone used in the treatment of advanced prostate cancer. for injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. suspension) for the palliative treatment palliative treatment n. Treatment to alleviate symptoms without curing the disease. Palliative treatment A type treatment that does not provide a cure, but eases the symptoms. Mentioned in: Laparoscopy of advanced prostate cancer, to 2018. Sanofi-Synthelabo, Inc. is the United States marketing partner for the Eligard prostate cancer products. "Eligard was previously protected under more general Atrigel system patents covering formulation of Atrigel with a 'biologically-active' agent," said Dr. Charles P. Cox, senior vice president of corporate development. "This new patent is specific to the composition of our proprietary Atrigel drug delivery system with leuprolide acetate, the active component in our Eligard prostate cancer products. By extending our proprietary position to 2018, we believe we have increased our potential revenue generating opportunity from the Eligard franchise." Currently, three Eligard prostate cancer products have been approved by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. and are available on the United States market; Eligard 7.5mg one-month duration product, Eligard 22.5mg three-month duration product and Eligard 30mg four-month duration product. A fourth Eligard product, Eligard 45mg six-month duration product, is in Phase III clinical testing. Atrix is an emerging specialty pharmaceutical company focused on advanced drug delivery. With five unique patented technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, pain management, and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or improve existing products. Atrix Laboratories, Inc. +1-970-482-5868 www.atrixlabs.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion